Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)
Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy): Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)
Study summary
The purpose of this study was to retrospectively analyze the wound condition, limb condition, ulcer recurrence and cardiovascular and mortality of patients with diabetic foot ulcer after admission to our hospital from 2009 to 2014, so as to understand the changes in the condition of patients with diabetic foot ulcer after treatment, provide evidence for the treatment of diabetic foot, and clarify the risk of diagnosis and treatment of diabetic foot.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥ 18 years old
2. Gender: males and females
3. Patients diagnosed with diabetic foot ulcers (including those on the Wagner scale 0-5)
4. Receive inpatient treatment during the designated study period
Exclusion Criteria:
1. Patients with severe systemic disease (such as end-stage renal disease, advanced cancer, etc.) may have influenced the study results
2. Patients unable to complete follow-up or with incomplete data
Primary outcome measure(s)
Ulcer healing rate in diabetic foot ulcers — Look at the last 10 years retrospectively
Ulcer recurrence rate in diabetic foot ulcer patients — Look at the last 10 years retrospectively
Amputation rate in diabetic foot ulcers — Look at the last 10 years retrospectively
Mortality of diabetic foot ulcers — Look at the last 10 years retrospectively
Trial sites (1)
Facility
City
Region
Status
National Clinical Medical Research Center for Metabolic Diseases (Shanghai)
Shanghai
China
More Shanghai Jiao Tong University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.